Introduction
The literature search was conducted using PubMed (www.ncbi.nlm.nih.gov/sites/entrez), entering the search term 'cystic fibrosis', for the period 1 January to 13 November 2007. There were 1228 papers identified; when limits were set for 'clinical trial' and 'randomized controlled trial' 63 papers remained. In addition, three meta-analyses were identified. The papers selected for this review are a personal choice of studies with important or interesting clinical messages.
Randomised controlled trials

Growth hormone
Schnabel D, Grasemann C, Staab D, Wollmann H, Ratjen F; German Cystic Fibrosis Growth Hormone Study Group. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics 2007;119:e1230-8.
What is already known? + Growth in cystic fibrosis (CF) is affected by malnutrition from a number of causes (e.g. pancreatic insufficiency, increased energy requirements etc.). + Chronically increased concentration of inflammatory cytokines (e.g. tumour necrosis factor-, interleukins 1 and 6) also adversely affects production and secretion of growth hormone (GH). + Many small, unblinded studies have been conducted, showing benefits in growth, nutritional status and lung function.
Methods + Twelve German centres participated in a double-blind randomized placebocontrolled trial, using two doses of daily somatropin GH for 24 weeks followed by 24 weeks open label. + All patients had body mass index (BMI) less than the tenth centile and/or weight less than the third centile; bone age was 8-18 years.
Results
+ Sixty seven patients were enrolled with a mean age around 14 years, and height and BMI Z scores around −2. + Height, growth velocity and growth factors (insulin-like growth factor 1 and insulin-like growth factor binding protein 3) increased significantly in both treatment groups. + Weight did increase but weight gain was no different from placebo. + Forced expiratory volume in 1 sec (FEV 1 ) did not change significantly, there was a trend to increase in forced vital capacity (FVC) in the higher dose group. + Maximal oxygen uptake (VO 2 max) during peak exercise increased significantly. + No problems with glucose metabolism.
Critique + GH had positive effects on metabolism but did not result in short-term improvement in lung function. + An important study as this was a relatively large trial of GH and the first to be placebocontrolled. However 300 patients would have been required to show a significant difference in FEV 1 . This illustrates the problem with clinical trials in CF that often require large subject numbers to prove significance. + It is unlikely many CF teenagers would accept daily injections with GH simply to grow more. + The authors suggest long-term studies in a larger cohort of patients are needed to clarify whether GH has a positive effect on lung function decline. I would suggest the time, money and effort are better spent studying other interventions. and difficulties with the logistics of therapeutic monitoring (serum levels) have meant that the use of ibuprofen is limited, especially in the UK, but also in many US centres. + Since the completion of this trial, there has been a publication of observational data from the CF Foundation Patient Registry looking at children with similar demographics to the trial (6-17 years with baseline FEV 1 >60%). They found a reduction in rate of decline over 2-7 years of FEV 1 in those taking ibuprofen (n=1365) compared to those not (n=8960). 2 Those taking it were more likely to have an episode of gastrointestinal bleeding requiring hospitalization (annual incidence 0.37% versus 0.14%).
Ibuprofen
Methods
+ Twelve Canadian centres participated in a multicentre double-blind randomized placebo-controlled trial of high dose ibuprofen (20-30 mg/kg twice daily) for two years.
Results
+ One hundred and forty-two patients were enrolled aged 6-18 years with a baseline FEV 1 >60% (i.e. they had mild lung disease). + Treatment group had a significant reduction in rate of decline of forced vital capacity (FVC) (+0.07% versus −1.62% predicted). + There was no change in FEV 1 , chest radiograph scores or nutritional status. + The therapy was well tolerated.
Critique + Unfortunately the study was grossly underpowered: 142 enrolled instead of the 440 required from sample size estimates. + Change in FVC may have been statistically significant but it was likely to be clinically insignificant. + This study is unlikely to change practice. Deterding P2Y 2 agonists may be useful, as they activate an alternate chloride ion channel, inhibit sodium absorption and enhance airway clearance. This was a multicentre, double-blind, randomized, placebo-controlled phase II study of nebulized denufosol tetrasodium given three times daily for 28 days. Eighty-nine subjects aged 8-45 (median 14) years took part, with mild CF lung disease (baseline FEV 1 >75% predicted). The study found the drug significantly improved lung function, albeit by only small amounts, and was well tolerated.
Nebulized denufosol tetrasodium
Inhaled corticosteroids
de Boeck K, de Baets F, Malfroot A, Desager K, Mouchet F, Proesmans M. Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients? Eur J Pediatr 2007;166:23-8.
This was a multicentre, double-blind, randomized, placebo-controlled trial of high dose inhaled fluticasone propionate given twice daily for one year. Twenty-seven children were enrolled with mild disease (baseline FEV 1 around 90% predicted). There was no difference found in lung function. Importantly, however, longitudinal growth was significantly slower in those on inhaled corticosteroids -3.96 versus 5.49 cm in one year -which resulted in a significant change in height standard deviation scores (−0.38 versus −0.01). There was no catch-up growth noted in the 1-2 years after the drug was discontinued. Given the lack of evidence for benefit of inhaled corticosteroids, this is a warning of potential harm. Critique + Epidemiological studies can only identify associations, not cause and effect. Because chest physiotherapy was more prevalent in LQ centres, it does not follow that physiotherapy is bad for the patients. Equally, it would be wrong to jump to the conclusion that oral corticosteroids were good for infants; furthermore, mast cell stabilizers have never been shown to be of value in infants with CF. + A limitation of the study is that two cross-sectional cohorts were used, it would have been more powerful if the infant cohort was followed until old enough to perform lung function. Only 525 of 1498 children (35%) from the infant cohort were included in those who had lung function. The study gives no information on treatment benefit in individuals, only on treatment in CF centres. + Their conclusion that 'pulmonary function of older children may be improved through specific interventions during the first 3 years of life' may be correct but unfortunately this paper cannot tell us which interventions. Critique + This is the largest study to look at the impact of MRSA and clearly there are additional adverse effects on lung function compared to MSSA. + Increased hospitalizations may be due to the fact that oral antibiotic choice is more limited for MRSA. + The nature of the study can not determine whether MRSA led to a reduction in lung function or whether MRSA is simply a marker of more severe lung disease. + The study also provides no information on the interaction of MRSA with P. aeruginosa.
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Cochrane systematic reviewsnew or substantially amended in 2007
Oral anti-pseudomonal antibiotics The review found no conclusive evidence that an oral anti-pseudomonal antibiotic regimen is more or less effective than an alternative treatment for either exacerbations or long-term treatment of chronic infection with P. aeruginosa.
CFTR gene replacement
Lee T, Southern KW. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
Cochrane
Database of Systematic Reviews 2007;2:CD005599. DOI: 10.1002/14651858. CD005599.pub2.
The review concluded that there is currently no evidence to support the use of CFTR gene transfer reagents as a treatment for lung disease in people with CF.
Oral calorie supplements
Smyth R, Walters S. Oral calorie supplements for cystic fibrosis. Cochrane Database of Systematic Reviews 2007;1:CD000406. DOI: 10.1002/ 14651858.CD000406.pub2.
The reviewers stated that oral calorie supplements do not confer any additional benefit in the nutritional management of moderately malnourished children with CF over and above the use of dietary advice and monitoring alone. While nutritional supplements may be used, they should not be regarded as essential.
